ZIVO Bioscience Expands Algae Cultivation for Compliance and Scaling Studies
KEEGO HARBOR, Mich., Feb. 02, 2017 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a company dedicated to the development and commercialization of nutritional compounds and bioactive molecules derived from its proprietary algal strains, announces that the Company has entered into a tolling agreement and technical services contract with Synthetic Genomics, Inc., (SGI) based in La Jolla, California.
ZIVO has engaged SGI to produce biomass in sufficient quantity to satisfy the sample production demands for validation in a variety of compliance studies and tests, ranging from basic toxin screening through more sophisticated digestibility and protein quality tests, as well as safety testing to meet GRAS (Generally Recognized As Safe) requirements for food and feed applications. These tests and studies have grown in number and scope since late April 2016 as the Company scaled up production to establish and test the parameters of commercialization.
The algal biomass production is conducted under rigorous controls to provide a framework for anticipated cGMP (current Good Manufacturing Practice) certification as required by state and federal food safety regulations. The initial biomass cultivation is being carried in small bioreactors and indoor ponds, and is then expected to move to larger, outdoor ponds within the next two weeks. Special inflatable greenhouse canopies placed over the outdoor cultivation ponds will help protect the algae from temperature extremes and windblown debris, thus insuring high-quality samples for the Company’s compliance and validation efforts.
The Company will continue its initiatives to bring algal biomass and high-value extracts into compliance and into the market. Additional sites are being evaluated for more cultivation capacity.
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc. (OTC:ZIVO.QB) is a Michigan-based biotech company engaged in the investigation of the health benefits of nutritive components derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
Contact: Investor Relations (248) 452 9866 ext 150 ZIVO Bioscience, Inc. Info@zivobioscience.com
Released February 2, 2017